Inspectors cite Calder Vale Peptides of Skipton over sterility assurance
The observation that closes a facility is rarely the dramatic one.
Archive — October 2024
Page 5 of 5 of this archive, newest first.
Nigeria caps liraglutide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
LEADER extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Six words a verification badge would need to mean anything
Every step between the laboratory report and the product page removes information, and the badge is the last step.
Repackaging, subdivision, and the batch number that changed hands
The interval between manufacture and analysis is the most under-read figure on the page, and the one most likely to matter by the time a vial is opened.
The one randomised trial that combined an incretin with supervised exercise
One randomised trial has combined a GLP-1 receptor agonist with supervised exercise. Its result is the single most useful piece of evidence in this area.
A shortage listing ends. 11 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of the consolidator trading as Meridian Freight Partners
A proper account of an operation that existed, and of what closing it cost.
Independent analysis puts a TFC tirzepatide lot at 97.7%, against 95.0% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
SSA declines, for the 15th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.